Thyroid therapy
-
Acella NP Thyroid recall: maternal risk inflated
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 2 of a two-part series reviewing the drug recall notice’s statements and the science behind them. [Part 1: Acella NP Thyroid recall: Ethical yet low-risk] We should applaud Acella for being so conscientious about the exact amounts…
-
Acella NP Thyroid recall: Ethical yet low-risk
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 1 of a two-part series reviewing the drug recall notice’s statements and the science behind them. In this post, I put this recall in the context of pharmaceutical guidelines and manufacturing challenges. I also portray the variable…
-
Review: Hoang’s 2013 study of LT4 and desiccated thyroid
In this review, I outline the strengths and weaknesses of Hoang et al’s clinical trial of levothyroxine (LT4) and desiccated thyroid extract (here called DTE, also known as NDT, natural desiccated thyroid).
-
Four definitions of thyroid status
We have a definition problem in thyroid science and thyroid therapy. A lot of confusion stems from the many definitions the words “euthyroidism,” “hypothyroidism” and “hyperthyroidism.” These are terms that can be defined in many ways by doctors, patients, and even by thyroid researchers. Is a person “hypothyroid” when their FT3 falls below their individual…
-
Japanese thyroid scientists examine symptoms in relation to FT3 and TSH
I would like to applaud a 2019 article by Mitsuru Ito and colleagues from the Center for Excellence in Thyroid Care at Kuma Hospital, Kobe, Japan. Dear researchers, your article, “Thyroid function related symptoms during monotherapy in athyreotic patients” showcased research on Free T3 levels and symptoms that is potentially meaningful to the life and…